Safety of bempedoic acid in patients at high cardiovascular risk and with statin intolerance

Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients

(2023) Steven E. Nissen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: A post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials

(2022) Lawrence A. Leiter et al.   DIABETES OBESITY & METABOLISM

High-Intensity Statin Use Among Patients With Atherosclerosis in the U.S.

(2022) Adam J. Nelson et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Assessment and management of statin-associated muscle symptoms (SAMS): A clinical perspective from the National Lipid Association

(2022) Bruce A. Warden et al.   Journal of Clinical Lipidology

Mechanism of action and therapeutic use of bempedoic acid in atherosclerosis and metabolic syndrome

(2022) Gianni Biolo et al.   Frontiers in Cardiovascular Medicine

Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of Bempedoic acid on cardiovascular events in patients with statin intolerance

(2020) Stephen J Nicholls et al.   AMERICAN HEART JOURNAL

Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials

(2020) Harold E. Bays et al.   Journal of Clinical Lipidology

Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association

(2019) Connie B. Newman et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries

(2019) Guy De Backer et al.   ATHEROSCLEROSIS

Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels

(2018) Marc S. Sabatine et al.   JAMA Cardiology

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol

(2018) Scott M. Grundy et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Targeting ATP-Citrate Lyase in Hyperlipidemia and Metabolic Disorders

(2017) Stephen L. Pinkosky et al.   TRENDS IN MOLECULAR MEDICINE

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias

(2016) Alberico L. Catapano et al.   ATHEROSCLEROSIS

Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia

(2016) Leopoldo Perez de Isla et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis

(2016) Stephen L. Pinkosky et al.   Nature Communications

Statin Intolerance

(2015) David H. Fitchett et al.   CIRCULATION

National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1—Full Report

(2015) Terry A. Jacobson et al.   Journal of Clinical Lipidology

Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease

(2013) Peter P. Toth et al.   Journal of Clinical Lipidology

Statins and new-onset diabetes—the important questions

(2012) David Preiss et al.   Nature Reviews Cardiology

Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy

(2011) David Preiss   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

(2010)   LANCET

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

(2010) Naveed Sattar et al.   LANCET

The JUPITER Trial

(2009) Paul M Ridker  

The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS)

(2008) Connie B Newman et al.   Diabetes & Vascular Disease Research

Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes (AFORRD): a randomised controlled trial

(2008) R. R. Holman et al.   DIABETOLOGIA

Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein

(2008) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE